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Health-related quality of life (HRQoL) is important in 
the management of basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC). Disease-specific ques-
tionnaires exist, but with important shortcomings. The 
aim of this study was to develop and validate a ques-
tionnaire suitable for use in all patients with BCC and 
those with SCC. In a 4-phase trajectory, a preliminary 
questionnaire was created and population-based tes-
ting (1,173 patients) carried out. The questionnaire 
was reduced using exploratory factor analysis and 
item response theory. Individual item performance 
was assessed using classical test theory. A total of 721 
patients completed the questionnaire. The number of 
items was reduced to 16, covering 5 scales. Confirma-
tory factor analysis showed a good fit. Cronbach’s αs 
(range 0.67–0.82) were reasonable to high with good 
internal consistency. In conclusion, the Basal and 
Squamous Cell Carcinoma Quality of Life questionnaire 
has good face, content and construct validity. It is use-
ful in the wide range of BCC and SCC patients and cap-
tures HRQoL impact over different time-frames.
Key words: basal cell carcinoma; squamous cell carcinoma; 
health-related quality of life; questionnaire.
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The use of patient-reported outcome measures (PROMs) and, more specifically, health-related 
quality of life (HRQoL) in dermatology patients has 
increased dramatically over the past decades. It is now 
an essential outcome for clinical studies and in daily 
practice, especially in chronic inflammatory skin diseases 
(1, 2). In skin cancer, the use of PROMs and HRQoL has 
only been used over the past 2 decades and most of the 
focus has been on melanoma (3). Since the incidences of 
basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC) are increasing rapidly (4–6), the need for PROMs 
assessment including HRQoL is warranted to evaluate 
individual and global disease burden. Generic, cancer- or 
even melanoma-specific HRQoL instruments are neither 
content-specific nor sensitive enough to detect the impact 
of the, rarely life-threatening, BCCs and SCCs, which are 
most often treated by conventional excision. Specific is-
sues for keratinocytic cancers is that patients are likely to 
develop multiple carcinomas and actinic keratosis (AK) 
(so-called actinic neoplasia syndrome) and that they can 
check their skin constantly (7).
Measurement of HRQoL in patients with BCC has 
been performed in several studies, using generic, cancer-
related and dermatology-specific questionnaires, all 
reporting little to no impact (7–13).
A few disease-specific questionnaires have been de-
veloped, but these have several important shortcomings. 
The Skin Cancer Index (SCI) was developed and tested 
only in a tertiary care Mohs surgery clinic and therefore 
is only suitable for use in a selected population (14, 15). 
The Skin Cancer Quality of Life Impact Tool (SCQO-
LIT) has been developed as a tool for patients with non-
metastatic skin cancer (16). A limitation of the SCQOLIT 
is that it addresses 5 psychological issues regarding 2 
different aspects in one item. In contrast to the SCI and 
the SCQOLIT, the Skin Cancer Quality of Life Ques-
tionnaire (SCQoL) was developed and validated using 
modern test theory, namely Rasch analysis (17). This 
instrument was, however, derived from the previously 
developed Actinic Keratosis Quality of Life question-
naire (AKQoL) and pre-tested in a small sample (18 AK 
patients, 14 skin cancer patients) with the objective of 
distinguishing between patients with AK and those with 
skin cancer (18). From a content validity perspective, 
the above-mentioned questionnaires do not capture the 
psychological issues due to the behavioural changes often 
required to reduce sun exposure (19).
The objective of this study was to create and validate 
a HRQoL questionnaire suitable for use with patients 
with BCC and those with SCC, addressing relevant is-
sues for patients and healthcare providers using different 
methodological approaches.
METHODS
Study design
The BCC- and SCC-specific HRQoL questionnaire was prepared 
and developed following the guidelines of the European Orga-
nisation for Research and Treatment of Cancer Quality of Life 
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(EORTC QOL) group as far as possible (20–22). However, the 
questionnaire is not an EORTC QOL group product and was not 
developed internationally. The development was conducted in 4 
phases, as follows.
Phase I. The main goal of phase I was to generate an extensive 
list of HRQoL issues relevant to patients with BCC and those 
with SCC. A focus group meeting to discuss and generate HRQoL 
issues was facilitated by 2 independent psychologists with no 
in-depth skin cancer knowledge. The group consisted of 10 BCC 
and/or SCC patients with different types and numbers of tumours, 
treatments, sex and age. The audio-recording of the focus group 
was analysed by the first author (RWS) in order to extract as 
many issues as possible without formal transcription. Extensive 
searches of the literature via PubMed (quality of life; health-related 
quality of life; basal cell carcinoma; squamous cell carcinoma; 
non-melanoma skin cancer) and semi-structured interviews with 
5 healthcare providers (HCP) provided additional issues (23). 
The issues were discussed by an expert panel including dermato-
logists, psychologists and epidemiologists to identify the relevant 
disease-specific domains and issues (Fig. 1).
The remaining issues were presented to HCP (dermatologists, 
plastic surgeons, ophthalmologist, head-neck ear nose and throat 
(ENT) surgeon, general practitioners) and patients for feedback 
and cognitive debriefing. They were also asked to rate the issues 
for relevance from 1 (not relevant) to 4 (very relevant) on a Likert 
scale (relevance rating). Issues with relevance mean score ≥1.5 
were selected for priority rating. HCP and patients were asked to 
select 15 core issues to be included in the questionnaire (priority 
rating). Priority ratings of ≥30% were scored in the HCP group 
and ≥20% in the patient group. Issues scoring ≥3 criteria were 
included in the final issue list (20). 
Phase II. The final issue list was rephrased into questions compat-
ible with the EORTC QLQ-C30 in terms of format of response 
categories (24). The time-frame of the questions was divided 
into 3 parts (“since diagnosis”, “time between diagnosis and 
treatment” and “during the past week”) since the items fitted dif-
ferent time-frames. 
Phase III. The item questionnaire was pre-tested in 16 patients. 
Phase IV. The questionnaire was field-tested in 1,173 patients 
selected from the Netherlands Cancer Registry, as collected by 
the Comprehensive Cancer Centre Netherlands, in Eindhoven. 
Patients were selected if they had been diagnosed in one of the 9 
participating hospitals or clinics during the past 12 months before 
the field-testing. The aim of the field-testing was to determine 
scale structure, reliability, validity and to reduce the number of 
items. The Skindex-17 and the QLQ-C30 were also administered.
Statistical analysis
Descriptive statistics (means and percentages) were used in phase 
II to calculate relevance and priority ratings of the issue list and 
in phase IV to describe the patient characteristics. Type of BCC 
was grouped as multifocal (8091 in the International Classification 
of Disease for Oncology; ICD-O3), infiltrating (8092), nodular 
(8097), or other (8090, 8093, 8094, 8095). Aforementioned analy-
ses were performed in IBM SPSS Statistics for Windows, Version 
21.0 (Armonk, New York: IBM Corporation).
After phase IV, the components were determined using principal 
component analyses (PCA) with varimax rotation. The number of 
components was determined with a Monte Carlo PCA for parallel 
analysis (25). Two PCAs were performed; one with complete cases 
and one with mean substitution, with a maximum of one missing. 
Items with loadings > 0.40, were selected for item response theory 
(IRT) (26). IRT was used to select a minimum number of the best 
discriminating items covering the whole range of latent traits. 
For IRT analysis, we applied the 2-parameter latent trait model 
(2PL-ltm) (27) of the ltm package in R version 3.0.0. The 2PL-
ltm program results in an ordering of the items on a given trait or 
component and supplies a discrimination value for each item. The 
2PL-ltm programme needs binary items as input. By collapsing 
the 4-answer category to binary items, some loss of information 
is induced. This method is preferred over multi-category models, 
because these do not provide an ordering of the items. 
The original categories were “not at all”, “a little”, “quite a 
bit“ and “very much”. For the majority of items the median was 
between the first and second category, and for this reason we 
dichotomized between “not at all” and “a little” or more.
The items were selected on the basis of their position on the 
relevant trait or component and their discriminative value. As 
we postulated an absolute maximum of 5 items per subscale, we 
divided the range between the lowest and highest position by 
5, and we chose from each of these intervals the item with the 
highest discriminative value. We checked the unidimensionality 
of the remaining items with the “unidim” test of the ltm package.
After the item reduction by the 2PL-ltm model, item perfor-
mance features as used in classical test theory (CTT) were tested. 
The definitions of the features are presented in Table SI1 (28, 29). 
Descriptive statistics were used to test item difficulty (missing 
responses) and response distribution. Spearman’s correlation coef-
ficients were calculated for item-test and item-rest correlation, and 
to test item discriminant validity. Internal consistency was tested 
via Cronbach’s α coefficients. Stepwise regression was performed 
in order to check the percentage of variance explained by the items 
in a subscale. The multitrait-multimethod correlation matrix was 
used to assess convergent and discriminant validity.
The resulting factors were also tested with oblique confirma-
tory factor analyses. We applied 2 analyses; a complete cases 
analysis and a maximum likelihood analysis with missing values. 
The fit indices were evaluated according to the recommendations 
of Hu & Bentler, Kline, and Brown (30–32). The correlations 
between the subscales were reported. The confirmatory factor 
analyses were performed with STATA version 14.1 (College 
Fig. 1. Questionnaire development phases. HCP: healthcare 
professional; BCC: basal cell carcinoma; SCC: squamous cell carcinoma. 
Phase number as described by the European Organisation for Research 
and Treatment of Cancer quality of life (EORTC QOL) group guidelines. 1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2806
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
R. Waalboer-Spuij et al.236
www.medicaljournals.se/acta
Station, TX, USA). All p-values were 2-sided and considered 
significant if α < 0.05.
RESULTS
Phase I–IV
The focus group meeting resulted in 63 issues, which 
were extended to 108 issues after literature searches 
and HCP interviews (Fig. 1). After an expert consensus 
meeting 51 issues were removed from the list due to over-
lapping issues, questions concerning information about 
the disease, cancer generic issues, or other problems 
that were considered outside of the domain of HRQoL. 
The remaining 57 issues were rated (mean scores, 
range, relevance and priority rating) by 42 patients (mean 
age 70 years, 1–30 years since diagnosis, 27 BCC, 5 SCC 
and 10 diagnosis unknown to the patient) and 15 HCP 
(7 dermatologists, 1 plastic surgeon, 1 head neck ENT-
surgeon, 1 ophthalmologist, 1 radiation oncologist and 
4 general practitioners) and resulted in the removal of 
the 24 issues with lowest relevance and priority ratings 
(Fig. 1).
The remaining 33 issues were constructed into a pro-
visional 33-item questionnaire (Table SII1).
This provisional questionnaire was reviewed by 16 
patients for readability, clarity of the items and overlap-
ping of the items and none of the items were excluded 
or rephrased.
Field testing was performed by selecting 1,173 patients 
with BCC or SCC from 9 hospitals. The response rate was 
61% and 721 patients completed the questionnaire (Table 
I). Of all respondents 85% had BCC and 15% had SCC.
The data contained 582 complete cases, 63 cases with 
one missing value and 76 cases with more than one 
missing value. 
Principal component analyses
The 2 PCAs (complete cases and with one missing inclu-
ded) both resulted in 6 components, with the same items 
loading. Items 23 and 24 formed a separate component, 
and at face value these items are nearly identical. Lea-
ving out one of them resulted in 5 components. Item 24 
had a higher factor loading than item 23; for this reason 
item 23 was removed from the analyses. Only item 5 
Table I. Patient characteristics
Respondents
n = 721
Non-
respondents
n = 264
Unverifiable 
addresses
n = 188 p-value
Sex, % 0.0063
Male 51 37 49
Female 49 63 51
Age
Mean ± SD 67.3 ± 1.8 71.4 ± 13.5 61.3 ± 15.1 < 0.0001
Median, IQR 68, 15 74.5, 16 61.5, 22.5
< 39 years 1 2 9 < 0.0001
40–49 years 8 7 16
50–59 years 14 9 21
60–69 years 31 18 22
70–79 years 32 33 18
> 80 years 14 31 13
SCC (%) 15 16 9 0.0560
Socioeconomic status
Low 17 22 13 < 0.0001
Intermediate 28 29 20
High 29 31 18
Institute 3 4 4
Unknown 23 13 46
Location of tumour
Face 78 78 85 0.1000
Other 22 22 15
Other skin tumoursa
Multiple BCC 16 19 11 0.1000
Multiple SCC 9 7 6 b
MM 0 0 1 b
Other 0 0 0 b
BCC, n 613 222 171
Type BCC, %
Multifocal 11 8 9 0.070
Infiltrating 18 22 15
Nodular 64 65 65
Other 7 4 12
aPatients can have combinations. bNo statistical test performed due to low numbers.
SD: standard deviation; IQR: interquartile range; BCC: basal cell carcinoma; SCC: 
squamous cell carcinoma; MM: malignant melanoma.
Table II. Subscales and item characteristics
Missing 
values
Principal 
component 
loading
2PL-ltm solution Selected 
BaSQoL 
items
Unidim
p-valuePosition Discrimination
Worries α=0.82 0.0297
19 2 0.764 0.013 2.609 10 ●
17 1 0.724 –0.404 3.056 9 ●
25 0 0.696 0.249 2.079 12 ●
26 0 0.665 –0.164 2.206
21 2 0.646 0.827 2.472 11 ●
28 0 0.630 –0.458 2.357
18 1 0.626 –0.219 2.247
24 1 0.482 –0.115 0.619
10 2 0.401 0.035 1.112
Appearance α=0.71 0.6733
33 0 0.787 1.239 5.025 15 ●
31 1 0.779 1.151 4.414
29 0 0.770 1.144 3.987
22 2 0.725 1.008 3.389 13 ●
30 3 0.661 1.253 3.06
15 1 0.580 a
32 9 0.459 1.981 2.251 14 ●
Behaviour α=0.79 0.6931
9 0 0.838 0.162 3.985 4 ●
4 7 0.763 0.212 2.357
6 1 0.760 0.028 2.479
1 1 0.748 –0.099 2.846 1 ●
2 2 0.741 0.296 2.79 2 ●
3 5 0.568 0.748 1.297 3 ●
5 1 0.349
Diagnosis and treatment α=0.78 0.7426
12 7 0.797 0.34 5.472 7 ●
14 2 0.745 0.624 2.146
13 1 0.686 0.654 2.381
11 1 0.610 –0.17 1.955 6 ●
16 2 0.509 –0.942 2.288 8 ●
Other people α=0.67 1.000
8 2 0.809 –0.403 2.362 5 ●
7 1 0.790 –0.491 2.299
27 2 0.705 0.130 3.624 16 ●
20 0 0.572 0.048 2.017
aItem 15 prevented the program converging, this items also had a high loading 
on the treatment component (0.371).
Preliminary questionnaire item numbers are displayed in the first column (Table SII1).
2PL-ltm: 2-parameter latent trait model; BaSQoL: Basal and Squamous cell 
carcinoma Quality of Life questionnaire.
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was not eligible, because it had a component loading 
lower than 0.40.
The 5 components were labelled as: Worries (8 items, 
α = 0.87), Appearance (7 items, α = 0.84), Behaviour (7 
items, α=0.85), Diagnosis & Treatment (5 items, α = 0.84) 
and Other people (4 items, α = 0.79) (Table II). 
Item response analyses
The position on the components and discrimination 
values resulting from the 2PL-ltm analyses are shown 
in Table II. On the basis of these values the item set was 
reduced from 32 to 16 items. The characteristic curves 
of the selected items are shown in Fig. 2. The “Wor-
ries” and “Behaviour” subscales retained 4 items (αs 
0.79–0.82), the “Appearance” and “Diagnosis & Treat-
ment” subscales retained 3 items (αs = 0.71–0.78) and 
the “Other people” subscale retained 2 items (α = 0.67). 
The unidim p-value for the 4 selected items of “Worries” 
was significant (p = 0.03), indicating that this subscale 
was not sufficiently unidimensional. This lack of uni-
dimensionality was caused by item 21. However, the 
unidim p-value of all 9 items was 0.38 indicating that 
all 9 items (including 21) belonged to a unidimensional 
subscale. We decided to include the item in the final 
questionnaire because we considered it to be a concep-
tually important aspect and because of the marking of 
the scale of the highest position on the latent trait. Item 
15 in the “Appearance” prevented the program from 
converging. Inspection of this item showed that it also 
loaded (0.37) on the “Diagnosis & Treatment” subscale, 
and thus violated the unidimensionality assumption. It 
was decided to delete this item from the analyses. After 
this the unidim test was insignificant for the subscales 
appearance, behaviour, diagnosis & treatment, and other 
people, indicating that the unidim assumption has been 
met for these subscales.
The resulting 16-item questionnaire was named the 
Basal and Squamous Cell Carcinoma Quality of Life 
(BaSQoL) questionnaire (Table SIII1).
Classical test theory
The 8 CTT item performance features of the newly 
constructed questionnaire showed that 7 out of 16 items 
showed only one suboptimal feature and one showed 2 
suboptimal performance features (Table III). From a 
CTT perspective, the overall performance of the BaSQoL 
is therefore considered to be good. There was no signi-
ficant correlation with the subscales of the Skindex-17 
and the QLQ-C30, suggesting that different issues were 
captured.
Confirmatory factor analyses 
Both the complete cases and the maximum likelihood 
with missing vales (MLMV) had acceptable to good 
misfit scores (RMSEA and SRMR) and good goodness 
of fit (CFI and TLI) (Table IV). The correlations between 
Fig. 2. Item characteristic curves of the subscales. The item characteristic curves depict the placement of the items on a latent ability and its 
discriminative value. For example, item 3 (provisional item number) discriminates best between patients with a high behavioural score, and item 1 
discriminates best in patients with a low score. In addition, item 9 discriminates better than item 3.
Table III. Item performance of the Basal and Squamous cell carcinoma Quality of Life (BaSQoL) questionnaire
BaSQoL subscales
Behaviour
Other 
people
Diagnosis & 
treatment Worries Appearance
Other 
people
BaSQoL item number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Item performance features
  Item difficulty
  Response distribution • • •
  Item-test correlation
  Item-rest correlation
  Item discriminant validity
  Item complexity
  Internal consistency • •
  Stepwise regression • • • •
Provisional 33-item questionnaire number 1 2 3 9 8 11 12 16 17 19 21 25 22 32 33 27
•Indicates suboptimal performance in a given item feature. Definition of suboptimal performance in Table SI1.
Item numbers displayed are the final BaSQoL item numbers (Table SIII1).
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the subscales were generally low and there were only 
small differences between the 2 analyses (Table SIV1).
Translation
The original Dutch version of the BaSQoL was transla-
ted into English by forward-backward translation (22) 
(Table SIII1).
Scoring
The individual items are scored from 0 to 3, where 0 
represents no impact and 3 very high impact. The mean 
score per subscale is calculated as a scale score. A mini-
mum of 50% of the questions within the subscale have 
to be answered in order to calculate the subscale score. 
There is no total score calculated for the instrument.
DISCUSSION
The BaSQoL questionnaire was developed methodo-
logically by following EORTC QOL group guidelines 
as closely as possible (20–22). It assesses the relevant 
dimensions of HRQoL in patients with BCC and those 
with SCC. 
The content of the BaSQoL questionnaire has some 
overlap with items from the existing questionnaires for 
skin cancer, such as cancer recurrence or spreading, 
concerns about scarring, and sun behaviour. However, 
the BaSQoL captures a broader spectrum of the issues 
relevant in patients with BCC and those with SCC, such 
as treatment- and diagnosis-related issues and long-term 
behavioural changes (14, 16, 17). Since our questionnaire 
was developed and validated in a large Dutch patient 
sample, by using a population-based approach, we con-
sider it to be representative for use in the wide range of 
patients with BCC and those with SCC.
Since patients were extensively involved in the whole 
process of development of the questionnaire, the ques-
tions are representative and are written in the terminology 
used by the patients.
By combining the use of modern IRT and CTT ana-
lyses we aimed to create a questionnaire with optimal 
psychometric properties. Therefore the BaSQoL has good 
face, content and construct validity. 
The use of different time-frames in our questionnaire 
is also a unique feature. Patients noted a difference in 
behaviour before and after the initial diagnosis. There-
fore the impact of this behavioural change is measured 
in the first part of the BaSQoL. The second part of the 
BaSQoL concerns the period of diagnosis and treatment. 
This, usually short, time-frame has a high impact on 
patients’ HRQoL. This subscale is suitable for assessing 
the patient’s experience of this specific period in order 
to manage anxiety during the process in case of new tu-
mours and, in general, to optimize patient care. The final 
part of the questionnaire addresses the impact of the skin 
cancer during the past week. Since BCC and SCC are 
being considered as more chronic diseases, it is important 
to address the relevant issues at the right moment.
The preliminary validation of the BaSQoL has also 
been established by this study. Cronbach’s αs of the 
reduced subscales remained reasonable, taking into ac-
count that a reduction in the number of items generally 
leads to a lower α (33, 34). The subscales are psycho-
metrically robust, displaying excellent item performance 
and a good fit in the confirmatory factor analysis. As 
the BaSQoL measures different aspects of HRQoL, it 
showed no significant correlation with the subscales of 
the Skindex-17 and the QLQ-C30, confirming divergent 
validity. Unfortunately, none of the previously developed 
BCC- or SCC-specific questionnaires were included 
in this study because there are no validated BCC- or 
SCC-specific questionnaires available in Dutch and we 
intended to minimize respondent burden and increase the 
response rate. A validation study of the English version 
of the BaSQoL is underway. Construct validity will be 
addressed in this study by comparison with the validated 
SCI, test–retest stability and responsiveness to change. 
Other important features to increase interpretability, 
such as categorization of scores and minimally clinical 
important difference, remain to be determined.
Item 21 (BaSQoL, nr 11) “Were you uncertain about 
the future?”, that violated the unidim assumption of the 
worries subscale, also had a suboptimal response distri-
bution (Table III). Confirmatory factor analysis, however, 
showed a good fit. This item reflects a more generic 
aspect than the other items in the subscale, it had, by far, 
the highest position on the latent trait for this reason, and 
because of the conceptual general intent of the item we 
decided to keep it in the questionnaire.
In summary, the BaSQoL has good face, content and 
construct validity. It is representative for use in the wide 
Table IV. Fit indices confirmatory factor analysis
Complete 
cases
Maximum likelihood
with missing values
Recommended 
Kline (31)
Recommended 
Hu & Bentler (30)
Recommended
Brown (32)
Measures of misfit: 
  Root mean squared error of approximation 0.050 0.053 < 0.05 ± 0.06 < 0.05/< 0.08*
  Standardized root mean squared residual 0.042 – < 0.10 ± 0.08 < 0.08
Goodness of fit:
  Comparative fit index 0.958 0.956 > 0.90 > 0.95
  Tucker-Lewis index 0.947 0.944 > 0.90 ± 0.95 > 0.95
*< 0.05: good; < 0.08 reasonable.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
239Development and validation of the BaSQoL questionnaire
Acta Derm Venereol 2018
range of patients with BCC and those with SCC and 
captures impact on HRQoL over different time periods. 
The BaSQoL will therefore be a useful tool to capture 
impact on HRQoL in future studies. 
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